The effect of methylphenidate (Ritalin ®) on the severity of stuttering.

The effect of methylphenidate (Ritalin ®) on the severity of stuttering. - The effect of methylphenidate (Ritalin ®) on the severity of stuttering.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004206-26-BE

Enrollment

Registered

2014-01-09

Start date

2014-02-10

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stuttering

Interventions

Trade Name: Rilatine Pharmaceutical Form: Capsule Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Men and women development Stuttering At least 18 years old Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Psychological disorders: depression, psychosis, bipolar disorder Psychogenic or neurogenic stuttering Children under 18 years ADHD narcolepsy Use of methylphenidate (now or in the past) Pregnant or breastfeeding AHT (blood pressure above 140/90) Use of benzodiazepines, neuroleptics such as haloperidol, amphetamines, anti-emetics such as metoclopramide and domperidone, L-dopa, MAO inhibitors Stroke or TIA hyperthyroidism Cocaine or other drug use (now or in the past) Drug addiction (now or in the past) glaucoma alcoholism Known liver disease epilepsy

Design outcomes

Primary

Measure	Time frame
Main Objective: Does methylphenidate effect on the severity of developmental stuttering in adults?;Secondary Objective: Not applicable;Primary end point(s): Measuring the number of : repeats sounds syllables words Middle Positions blockades Audibles silences stress;Timepoint(s) of evaluation of this end point: before administration of a single dose and 3 hours after the administration	—

Secondary

Measure	Time frame
Secondary end point(s): none;Timepoint(s) of evaluation of this end point: NA	—

Countries

Belgium

Contacts

Public ContactVakgroep Huisartsgeneeskunde

Vrije Universiteit Brussel

ddevroey@vub.ac.be

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026